Cognitive decline is part of the normal aging process. However, some people experience a more rapid decline than others due to environmental and genetic factors. Numerous single nucleotide polymorphisms (SNPs) have been linked to cognitive function, but only a few to cognitive decline. To understand whether cognitive function and cognitive decline are driven by the same mechanisms, we investigated whether 433 SNPs previously linked to cognitive function and 2 SNPs previously linked to cognitive decline are associated with both general cognitive functioning at baseline and general cognitive decline up to 20-years follow-up in the Doetinchem Cohort Study (DCS). The DCS is a longitudinal population-based study that enrolled men and women aged 20–59 years between 1987–1991, with follow-up examinations every 5 years. We used data of rounds 2–6 (1993–2017, n = 2559). General cognitive function was assessed using four cognition tests measuring memory, speed, fluency and flexibility. With these test scores, standardized residuals (adjusted for sex, age and examination round) were calculated for each cognition test at each round and subsequently combined into one general cognitive function measure using principal component analyses. None of the 435 previously identified variants were associated with baseline general cognitive function in the DCS. But rs429358-C, a coding apolipoprotein E (APOE) SNP and one of the variants previously associated with cognitive decline, was associated with general cognitive function cross-sectionally ($p$-value = $1 \times 10^{-5}$, Beta = $-0.013$). These findings suggest that decline of general cognitive function is influenced by other mechanisms than those that are involved in the regulation of general cognitive function.

INTRODUCTION

For healthy aging it is essential to maintain optimal cognitive function throughout the course of life. Preserving good cognitive function is important to remain self-reliant and to prevent or postpone cognitive impairment and dementia [1]. Decline in cognitive function is part of the normal aging process [2], but there is large inter-individual heterogeneity in the rate of decline. Moreover, accelerated cognitive decline is a predictor of dementia and mortality [3–5]. Multiple risk factors that negatively affect cognitive function and cognitive decline are known, such as lifestyle factors (physical inactivity, smoking, unhealthy diet), metabolic factors (hypertension, obesity, diabetes mellitus), and a lower educational level [6–9]. In addition to these (partly) modifiable factors, genetic factors play an important role. For example, it has been shown that apolipoprotein E (APOE) ε4 carriers have accelerated cognitive decline, while APOE ε2 carriers have decelerated cognitive decline compared to ε3 carriers in middle aged and older adults [10, 11]. In addition, it has been shown that already in childhood APOE ε4 affects cognitive performance [12].

Studying the role of genetic factors, through for example genome-wide association studies (GWASs), could disclose underlying biological mechanisms affecting cognitive health. In addition, it may be of even greater value to identify single nucleotide polymorphisms (SNPs) associated with a decline in cognitive function, rather than with cognitive functioning at a single point in time. This may reveal specific mechanisms behind cognitive decline, preceding cognitive impairment and dementia. In addition, genetic markers can also help identify people who are at risk of (accelerated) cognitive decline and possibly postpone or reduce cognitive decline, for example by increasing the cognitive reserves [13].

Numerous SNPs have been linked to cognitive function. In a recent GWAS by Davies and Lam et al., including over 300,000 participants, 434 independent SNPs (i.e. SNPs with a $p$-value of $\leq 5 \times 10^{-8}$ and $r^2 < 0.6$) in 148 genomic loci were associated with general cognitive function cross-sectionally [14]. Only a few SNPs have been linked to cognitive decline in GWASs, possibly due to the limited number of cohort studies in which cognitive functioning is repeatedly measured. These studies showed that APOE is associated with cognitive decline in people with different genomic backgrounds [15–17]. Surprisingly, the APOE locus was not amongst the associated loci in the GWAS by Davies and Lam.
et al. on cross-sectional cognitive function [13]. This raises the question whether different genetically determined pathways influence the level of cognitive function and the rate of cognitive decline. Therefore, we investigated whether the recently identified independent SNPs by Davies and Lam et al. [14] along with two APOE SNPs, were associated with general cognitive functioning at baseline and general cognitive decline in the Doetinchem Cohort Study (DCS) over an extended period of time (up to 20-years follow-up) and with up to five repeated cognition measurements in older adults (n = 2559).

MATERIALS AND METHODS

Cohort

The DCS is a longitudinal population-based cohort study including 7769 men and women aged 20–59 years living in Doetinchem between in 1987–1991 (round 1). Adults who participated in the first round were invited for follow-up examinations in 1993–1997 (round 2, n = 6117, mean age: 46 years), 1998–2002 (round 3, n = 4918, mean age: 51 years), 2003–2007 (round 4, n = 4520, mean age: 56 years), 2008–2012 (round 5, n = 4018, mean age: 60 years), and 2013–2017 (round 6, n = 3438, mean age: 64 years). Response rates were 75% or higher in all rounds. The design of this study has previously been described in more detail [18, 19]. All participants gave written informed consent in each round. The study was approved by the Medical Ethics Committee of the Netherlands Organization of Applied Scientific Research and the Medical Ethics Committee of the University of Utrecht according to the guidelines of the Helsinki Declaration.

Measurements. Weight (kg), height (cm), waist circumference (cm), and systolic and diastolic blood pressure (mmHg) were measured according to standard protocols [19]. BMI was calculated as weight divided by height squared (kg/m²). Obesity was defined as BMI ≥ 30 kg/m².

Genotyping, quality control and imputation

Genomic DNA was isolated from venous blood samples of 5088 individuals at the Dutch National Institute for Public Health and the Environment, and genotyped in the Human Genomics Facility (HUGE-F) Rotterdam using the Illumina Infinium Global Screening Array-24 Kit (GSA) (Illumina Inc., San Diego, California, United States of America) [26]. The R package GenABEL 1.8-0 [27], was used to perform the quality control for both participants and genetic variants.

Participants were excluded if (Supplementary Fig. 1): (1) there was a sex mismatch (n = 45), (2) samples were duplicates (n = 18) or monozygotic twins (n = 1) (one individual per pair), (3) heterozygosity rate was high (false discovery rate (FDR) < 1%) (n = 37), (4) the sample call rate was <95% (n = 20), and (5) participants were widely diverged (i.e. being genetically distant based on visual inspection of a genomic principal component (gPC) plot) regarding their genetic background based on the first two gPCs that were constructed using a kinship matrix, in two steps (n = 114). First, the most distant participants compared to the group as a whole were excluded. Next, as a single iterative step new gPCs were generated in the remaining sample population and additional participants were removed.

Genetic variants were excluded when: (1) minor allele frequencies (MAF) were <1/20 (n = 5088, this is the population before quality control), i.e. the chance of finding the allele once in the study population, thus representing monomorphic variants (n = 109129), (2) genotype call rates were <95% (n = 8005), (3) variants were not in Hardy-Weinberg equilibrium (FDR < 0.2) (n = 0), and (4) X-linked markers were likely to be autosomal (n = 421). Subsequently, the HRC-1000G-check-bim.pl script from Rayner [http://www.well.ox.ac.uk/~wrayner/tools/HRC-1000G-check-bim.plscript] was used for quality control and to convert the Plink genotype data [28] to personnel following a standardized protocol. General cognitive functioning was measured using four tests assessing four domains: memory function, information processing speed, verbal fluency and cognitive flexibility. These four tests were the 15 Words Verbal Learning Test (VLT) (number of correct words on the delayed recall) [21], the Letter Digit Substitution Test (total of correct answers) [22], the Word Fluency Test (number of correct animals) [23], and the Stroop Color-Word Test (card III, i.e. total time needed for the interference test) [24]. The cognitive tests have previously been described in more detail [25].

The STROOP test was log-transformed. The other tests had a normal distribution. The first cognition measurement of a study participant was considered the baseline measurement, i.e. timepoint zero (T0). Since cognition measurements started when participants had reached the age of 45 and was introduced half-way in round 2 of the DCS, T0 was not confined to a particular round. Most participants had their T0 measurement in round 3, but there were also other participants who had their T0 measurement in round 2, 4, 5 or 6 (Fig. 1). Timepoints range from T0-T20 with 5-year intervals.

Genotyping, quality control and imputation

Genomic DNA was isolated from venous blood samples of 5088 individuals at the Dutch National Institute for Public Health and the Environment, and genotyped in the Human Genomics Facility (HUGE-F) Rotterdam using the Illumina Infinium Global Screening Array-24 Kit (GSA) (Illumina Inc., San Diego, California, United States of America) [26]. The R package GenABEL 1.8-0 [27], was used to perform the quality control for both participants and genetic variants.

Participants were excluded if (Supplementary Fig. 1): (1) there was a sex mismatch (n = 45), (2) samples were duplicates (n = 18) or monozygotic twins (n = 1) (one individual per pair), (3) heterozygosity rate was high (false discovery rate (FDR) < 1%) (n = 37), (4) the sample call rate was <95% (n = 20), and (5) participants were widely diverged (i.e. being genetically distant based on visual inspection of a genomic principal component (gPC) plot) regarding their genetic background based on the first two gPCs that were constructed using a kinship matrix, in two steps (n = 114). First, the most distant participants compared to the group as a whole were excluded. Next, as a single iterative step new gPCs were generated in the remaining sample population and additional participants were removed.

Genetic variants were excluded when: (1) minor allele frequencies (MAF) were <1/20 (n = 5088, this is the population before quality control), i.e. the chance of finding the allele once in the study population, thus representing monomorphic variants (n = 109129), (2) genotype call rates were <95% (n = 8005), (3) variants were not in Hardy-Weinberg equilibrium (FDR < 0.2) (n = 0), and (4) X-linked markers were likely to be autosomal (n = 421). Subsequently, the HRC-1000G-check-bim.pl script from Rayner [http://www.well.ox.ac.uk/~wrayner/tools/HRC-1000G-check-bim.plscript] was used for quality control and to convert the Plink genotype data [28] to

Fig. 1 Overview of cognition measurements (T0-T20) through rounds 2–6 in the Doetinchem Cohort Study. This figure shows the number of participants with one or more cognition measurements (from T0 up to T20 (time in years)) through rounds 2–6 of the Doetinchem Cohort Study (DCS) during the 20-year follow-up. Note: This figure includes all participants with cognition measurements in the DCS. In the present study, part of these participants were excluded (see Supplementary Fig. 1). T0 = blue, T5 = green, T10 = gray, T15 = orange, T20 = yellow.
separate VCF files per chromosome. This pre-imputation step of quality control filtered additional SNPs based on genotype call rate <98% (n = 15013) and Hardy-Weinberg p < 10⁻⁶ (n = 0). Finally, genotypes were imputed to the HaploTyper Reference Consortium (HRC) panel (version r1.1 2016) [29] with the Michigan Imputation Server [30] using NCBI Genome Reference Consortium Human Build 37. Pre-phasing was performed on the imputation server with Eagle v2.3 [29] and imputation with Minimac3 [31]. After quality control and imputation of the GSA-data, a total of 4853 participants were left for further analyses (Supplementary Fig. 1).

General cognitive function at baseline and during follow-up
For 4110 participants both genotype and cognition data were available (Supplementary Fig. 1). Before constructing the general cognitive function measure, participants without measurements on all four cognition tests were made missing for that particular round. Participants were excluded when: the previous steps resulted in missing values for the cognition tests at T0 (n = 45), had cognition measurements at only one time point (n = 768), or had a history of stroke (diagnosed or self-reported (n = 213)) at any measurement.

Using the four tests, we constructed a measure of general cognitive function as described by Davies and Lam et al. [14] and Trampush et al. [32]. In brief, sex-age and round-adjusted standardized residuals were calculated for each cognition test at each round. Next, these four adjusted test scores were combined into one general cognitive function measure using a principal component analysis. In the Supplementary Material, we describe each of these steps in more detail. After all the steps had been taken, also shown in Supplementary Fig. 1, 2559 participants were left to study the associations between SNPs and general cognitive function and decline.

SNP selection
Davies and Lam et al. identified 11,600 SNPs that were statistically significantly (p-value of ≤ 5 × 10⁻⁸) associated with general cognitive function cross-sectionally. Of these SNPs, they identified 434 ‘independent’ SNPs (at an r² cut-off < 0.6) [14]. They used NCBI build 37 as reference, which is the same build we used to impute our data. Since in previous GWAS it was shown that APOE gene variants are associated with age related cognitive decline [15, 16], this locus was also part of our interest. Hence, we added rs429358 (chromosome 19: base pair (bp) 19:45119441) and rs7412 (chr19: 19:45412079) to our SNP-dataset. Thus, we selected the 434 ‘independent’ SNPs and the two aforementioned exonic APOE SNPs for our study resulting in a total of 436 SNPs. Genetic variants with an imputation quality (R²) below 0.4 or a minor allele frequency (MAF) below 0.01 were not considered for analysis in the present study. Since one of the 434 ‘independent’ SNPs had a MAF < 0.01 (rs45107329, chr19: bp 1:22428398), the final SNP selection consisted of 435 SNPs based on 433 ‘independent’ SNPs and 2 APOE SNPs.

Statistical analyses
Population characteristics. Descriptive analyses were carried out in RStudio version 1.1.456 [33]. Trajectories of general cognitive function up to 20-years follow-up were visualized using ggplot2 version 3.0.0 [34].

Cross-sectional association between SNPs and general cognitive function at baseline. We studied the cross-sectional association between the 435 SNPs (independent variables) and general cognitive function at baseline (T0) (dependent variable). A linear regression model was fitted per SNP and in each model we adjusted for sex, age, and population stratification using the first two gPCs. The two APOE SNPs were also assessed as a haplotype, that is, rs429358 and rs7412 were combined to obtain the APOE genotypes (ε2ε2, ε2ε3, ε3ε3, ε2ε4, ε3ε4, and ε4ε4). There were no ε1 carriers present in this study population. Next, the participants were grouped in ε2 carriers (ε2ε2 and ε2ε3), ε3 homozygotes (ε3ε3), and ε4 carriers (ε2ε4, ε3ε4, and ε4ε4). Since the ε4 allele is dominant over the ε2 allele [39], ε2ε4 genotypes were included in the ε4 carriers-group. To study the longitudinal association between the four APOE groups (independent variable with ε3 homozygotes as reference group) and decline in general cognitive function (T0-T20) (dependent variable) we used the same model as used to study the longitudinal association between the 435 SNPs and general cognitive decline (see section above). A p-value of 0.1 was considered statistically significant since we were interested in the interaction term APOE haplotype group*time.

Polycgenic profile score analyses. A polycgenic profile score was calculated based on 399 out of the 435 independent SNPs. The palindromic SNPs (n = 36) were excluded from these analyses. The polygenic profile score was calculated using PLINK (version 1.90) based on the summary statistics of the 399 independent variants of Davies and Lam et al. [14]. The proportion of explained variance (R²) was calculated using a linear regression model per time point (T0-T20). A separate linear regression model was used to examine the cross-sectional association between the polygenic profile score and general cognitive function at baseline, adjusting for age at baseline, sex, and population stratification using the first two gPCs. To study the longitudinal association between the polygenic profile score and general cognitive decline we used a linear mixed model adjusting for sex, age at baseline, and population stratification using the first two gPCs. In addition, we included time (0–20-years with 5-year intervals, i.e. five time points) into the model, and the interaction terms polygenic profile score*time and age at baseline*time. A p-value of 0.1 was considered statistically significant since we were interested in the interaction term polygenic profile score*time.

RESULTS
Population characteristics
The study sample consisted of 2559 participants at T0, 2434 at T5, 1832 at T10, 1423 at T15, and 130 at T20. There were 707 participants with two cognition measurements, 556 with three, 1184 with four, and 112 with five cognition measurements, resulting in 8378 observations. Participants did not always have consecutive measurements, meaning that participants could for example have cognition measurements at T0, T10, and T20. The population characteristics at baseline (T0) are summarized in Table 1. Figure 2 shows the trajectories of all 2559 participants for general cognitive function. We also visualized the trajectories of the sex, age and examination round-adjusted standardized residuals of the four individual cognition tests (Supplementary Figs. 4–7).

Cross-sectional association between SNPs and general cognitive function at baseline
After adjustment for multiple testing, none of the 435 SNPs were significantly associated with general cognitive function at baseline (Supplementary Table 1). The SNP with the lowest p-value we used LME4 version 1.1–17 [38]. This package can handle missing values, as long as each participant has at least two observations. A linear mixed model was fitted for each SNP and in each model we adjusted for sex, age at baseline, and population stratification using the first two gPCs. In addition, we included time (0–20-years with 5-year intervals, i.e. five time points) into the model, and the interaction terms SNP*time and age at baseline*time. For this model we used a correlated random intercept and slope, since participants with higher cognitive function at baseline (intercept) may have a steeper decline (slope), and vice versa. A p-value of 0.1, instead of 0.05, was considered statistically significant since we are now interested in an interaction term instead of a main effect. We corrected for multiple testing based on the Bonferroni adjustment (i.e. 0.1/435 = 2 × 10⁻⁴) for the interaction term SNP*time. Hence, a p-value < 2 × 10⁻⁴ was considered statistically significant.

Longitudinal association between the APOE haplotype group and general cognitive decline. The two APOE SNPs were also assessed as a haplotype, that is, rs429358 and rs7412 were combined to obtain the APOE genotypes (ε2ε2, ε2ε3, ε3ε3, ε2ε4, ε3ε4, and ε4ε4). There were no ε1 carriers present in this study population. Next, the participants were grouped in ε2 carriers (ε2ε2 and ε2ε3), ε3 homozygotes (ε3ε3), and ε4 carriers (ε2ε4, ε3ε4, and ε4ε4). Since the ε4 allele is dominant over the ε2 allele [39], ε2ε4 genotypes were included in the ε4 carriers-group. To study the longitudinal association between the three APOE groups (independent variable with ε3 homozygotes as reference group) and decline in general cognitive function (T0-T20) (dependent variable) we used the same model as used to study the longitudinal association between the 435 SNPs and general cognitive decline (see section above). A p-value of 0.1 was considered statistically significant since we were interested in the interaction term APOE haplotype group*time.
(p-value = 2 × 10^{-4}) was rs2782653 located at chr:bp 1:43950265. The alternative allele G was inversely associated with general cognitive function at baseline (Beta = −0.16) compared to the reference allele C.

Additional adjustment for level of education did not change the results (Supplementary Table 1). Supplementary Fig. 2 shows trajectories of general cognitive function stratified by education level up to 20-years follow-up.

### Longitudinal association between SNPs and general cognitive decline
After adjusting for multiple testing, rs429358, one of the two APOE SNPs, was statistically significantly associated with decline in general cognitive function (p-value = 1 × 10^{-5}, Beta = −0.013) with T as reference allele and C as alternative allele (Supplementary Table 2). Supplementary Fig. 3 shows the trajectories stratified by rs429358 genotype up to 20-years follow-up. None of the other SNPs were significantly associated with a decline in general cognitive function.

### Longitudinal association between APOE haplotype group and general cognitive decline
Table 2 gives an overview of the APOE haplotypes for the total population and for men and women based on rs429358 and rs7412. Supplementary Table 3 shows the APOE haplotypes stratified by education level. There was no significant longitudinal association between the ε2 carriers and ε3 homozygotes (reference category) for general cognitive decline. However, there was a statistically significant longitudinal association between the ε4 carriers and ε3 homozygotes (reference category) for general cognitive decline (p-value = 5 × 10^{-4}, Beta = −0.012). Figure 3 shows the adjusted trajectories of general cognitive function for the APOE haplotype groups based on this longitudinal association.

### Polygenic profile score analyses
At T0, 0.9% of the variance of general cognitive function is explained by the polygenic profile score (Table 3). At time points T5, T10 and T15, compared to T0, less variance of general cognitive function is explained by the polygenic profile score. At T20, a higher percentage (2.9%) of the variance of general cognitive function is explained by the polygenic profile score compared to the other time points. Further, we found a statistically significant cross-sectional association between the polygenic profile score and general cognitive function (Beta = 0.72, standard error = 0.15, p-value = 9.3 × 10^{-7}). The longitudinal association between the polygenic profile score and general cognitive decline was not statistically significant (Beta = 0.001, standard error = 0.007, p-value = 0.86).

### DISCUSSION
To understand whether cognitive function and cognitive decline are driven by the same mechanisms, we investigated whether 433

---

**Table 1.** Population characteristics at baseline (T₀).

| Characteristics at T₀ | N = 2559 |
|------------------------|----------|
| **Socio-demographic factors** | |
| Sex (men) | 47% |
| Age (years), median (IQR) | 53.0 (8.7) |
| Low education level | 41% |
| **Life-style factors** | |
| Physically inactive | 23% |
| Current smoker | 22% |
| Alcohol consumption (1 or more glasses/week) | 73% |
| **Anthropometric data** | |
| BMI (kg/m²), mean (SD) | 26.3 (3.9) |
| Obesity (≥30 kg/m²) | 14% |
| Waist circumference (cm), mean (SD) | 93.9 (11.3) |
| **Blood pressure** | |
| Systolic blood pressure (mmHg), mean (SD) | 129.2 (17.4) |
| Diastolic blood pressure (mmHg), mean (SD) | 81.6 (10.5) |
| **Health** | |
| Poor or fair self-reported health | 12% |

BMI body mass index, SD standard deviation, IQR interquartile range.
SNPs previously linked to cognitive function and 2 SNPs previously linked to cognitive decline were associated with both general cognitive functioning at baseline and general cognitive decline in the DCS. We found that rs429358-C, one of the APOE SNPs, was associated with long-term general cognitive decline, but not with general cognitive function at baseline. None of the other previously identified SNPs for cognitive function or decline were significantly associated with general cognitive function at baseline, nor with cognitive decline.

One of the strengths of the DCS is that cognitive functioning was repeatedly (up to five measurements) and objectively measured with a standardized, comprehensive, and validated neuropsychological test battery in adults over an extended period of time (up to 20-years follow-up), making this a unique cohort to study cognitive aging. In addition, for this study we used data from a single cohort, i.e. the DCS, and used an identical neuropsychological test battery at all examinations resulting in a more homogenous outcome than in a meta-analysis where the included cohorts often use different neuropsychological test batteries. A limitation to this study was the number of included participants. After applying all exclusion criteria there were 2559 participants left for the association analyses. The number of participants may have limited our power since general cognitive function is a complex trait for which a higher number of participants is likely to be needed to gain sufficient power [40].

We were unable to replicate the findings of Davies and Lam et al. [14], i.e. none of their 433 ‘independent’ SNPs were associated with general cognitive function at baseline in our study. However, we did find an association with the polygenic profile score and baseline general cognitive function. There are some explanations for these different results that need to be discussed. First, the age range in the DCS was 45–74 years at baseline, while the age range in the study of Davies and Lam et al. was 16–102 years. Cognitive function changes over the course of life and has an inverted U-shape in which the brain and cognitive functions of adolescents still develop [41], while older adults may experience cognitive decline due to ageing of the brain [42]. In both the DCS study as well as in the study of Davies and Lam et al., adjustment for age was performed. However, since age has such a strong impact on the level of cognitive function, it could still have affected the obtained results differentially. Second, the heterogeneous phenotype could also have influenced our results regarding baseline cognitive function. General cognitive function is a heterogeneous outcome in two respects. (1) Participants can score differently on the individual cognitive functioning tests while they can have the same score on the overall measure. For example, one participant can have a low memory test score, while another participant can have a low executive functioning test score. This can lead to the same overall score, i.e. general cognitive function, while they score differently on the underlying tests. Between studies, therefore, the average total score may not reflect similar underlying functioning of the participants. (2) Frequently, different tests are used to measure cognitive function in different cohort studies. In the DCS, the same neuropsychological test battery was used through all rounds for all participants. In the meta-analyses of Davies and Lam et al., data of multiple cohorts were used in which cognitive function was tested using different test batteries. As a result, phenotypic heterogeneity may be larger in the Davies and Lam study. Possibly, the phenotype of Davies and Lam et al. represents different aspects of general cognitive function compared to our phenotype. Although there is evidence to support ethnicity dependency of the APOE genotype on brain function, this is not likely to be an explanation for the observed differences as both the study of Davies and Lam et al. and our study only included individuals from European descent. Finally, we cannot exclude the possibility that we had limited power to detect the cross-sectional associations found in the Davies and Lam study, as we do find an association with the polygenic profile score and general cognitive function at baseline. Our study sample was considerably smaller compared to the number of participants included in the Davies and Lam study. On the other hand, our phenotype was probably more homogeneous than the phenotype of Davies and Lam et al., but this may not have outweighed the smaller number of observations.

The SNP with the lowest p-value (but not statistically significant after adjustment for multiple testing) associated with general cognitive function at baseline was rs2782653 (p-value = 2 × 10^{-4}, beta = –0.16) located at chr1p:43950265. The C allele was associated with a lower general cognitive function at baseline, which was similar to the effect found in the Davies and Lam study. Rs2782653 was previously found to be associated with lower attained education level in the UK Biobank [43, 44]. A sensitivity analysis, in which we adjusted for education level, did not change our results.

To verify a possible effect of selection bias in the longitudinal analyses, we studied the participation rate per APOE haplotype group for each time point and did not observe a selection bias (Supplementary Table 4). Our result for the longitudinal association between rs429358 in the APOE coding region and cognitive decline is in line with the three GWASs on cognitive decline [15–17]. De Jager et al. [16] identified rs4420638, another SNP at the APOE locus which is in strong LD (r^2 = 0.7) with rs429358 [45]. Davies et al. [15] also found rs429358 to be significantly associated with cognitive decline. Possibly we did not find a cross-sectional association between general cognitive function and the APOE SNPs cross-sectionally because rs4 carriers have a higher cognitive score but also a steeper decline and consequently no large differences between the different APOE genotypes are present at middle age. An alternative explanation might very well be that cognitive decline is influenced by different mechanisms than those involved in the regulation of the level of cognitive function at a certain time point. This hypothesis is supported by our finding that the APOE locus was significantly associated with cognitive decline, but not with

| Haplotypes  | Total N = 2559 | Men N = 1195 | Women N = 1364 | APOE groups |
|------------|---------------|-------------|----------------|-------------|
| ε2/ε2      | 1%            | 1%          | 1%             | r2 carriers |
| ε2/ε3      | 6%            | 7%          | 6%             | r2 carriers |
| ε3/ε2      | 6%            | 6%          | 6%             | r2 carriers |
| ε3/ε3      | 58%           | 58%         | 57%            | r3 homozygotes |
| ε3/ε4      | 11%           | 11%         | 11%            | r4 carriers |
| ε2/ε4      | 2%            | 2%          | 2%             | r4 carriers |
| ε4/ε2      | 1%            | 2%          | 1%             | r4 carriers |
| ε4/ε3      | 12%           | 12%         | 13%            | r4 carriers |
| ε4/ε4      | 3%            | 3%          | 3%             | r4 carriers |

Table 2. APOE haplotypes for the total population and for men and women separately.
cognitive function at baseline. This was also found in two studies of Davies, in which the APOE locus was not associated with cognitive function [14], but was associated with cognitive decline [15]. In addition, this was confirmed in a recent study that showed APOE ε4 status was not statistically significant associated with cognition level, but was associated with cognitive decline [46]. Another recent study showed that APOE ε4 carriers have accelerated breakdown of the blood-brain barrier (BBB) in the hippocampus and medial temporal lobe contributing to cognitive decline independent of Alzheimer’s disease pathology [47]. It could be hypothesized that APOE ε4 affects cognitive decline, but not the level of cognitive function, via breakdown of the BBB. However, early Alzheimer’s pathology, in particular amyloid plaques, could also have played a role [48–50]. Further, APOE protein expression levels in specific brain regions seem to add to the development of Alzheimer’s disease [51] and may therefore possibly also contribute to decline in general cognitive function.

In conclusion, we confirm that rs429358, and thereby the APOE locus, is significantly associated to general cognitive function at baseline. Baseline general cognitive function could be influenced by other mechanisms than those involved in the regulation of general cognitive decline.

**Fig. 3** Adjusted trajectories of general cognitive function for the APOE haplotype groups. This figure shows the adjusted trajectories of general cognitive function for three APOE groups (i.e. ε2 carriers, ε3 homozygotes and ε4 carriers) up to 20-years follow-up (n = 2559). T0-T20 represents time in years. The trajectories were adjusted for sex, age at baseline, and population stratification using the first two gPCs. In addition, we included time (0–20 years with 5-year intervals, i.e. five time points) into the model, and the interaction terms SNP*time and age at baseline*time.

**Table 3.** R² between the polygenic profile score and general cognitive function per time point.

| Time point | N     | Estimate | R²       | P-value |
|------------|-------|----------|----------|---------|
| 0          | 2559  | 0.611    | 0.0087   | 2.1 × 10⁻⁶ |
| 5          | 2434  | 0.497    | 0.0058   | 1.6 × 10⁻⁴ |
| 10         | 1832  | 0.445    | 0.0043   | 4.9 × 10⁻³ |
| 15         | 1423  | 0.471    | 0.0050   | 7.7 × 10⁻³ |
| 20*        | 130   | 1.081    | 0.0293   | 5.1 × 10⁻² |

*The participant rate at T20 is low because the data collection is still in progress.

REFERENCES

1. Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018;14:653–66.
2. Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464:529–35.
3. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain. 2005;128:1093–101.
4. Deeg DJ, Hofman A, van Zonneveld RJJ. The association between change in cognitive function and longevity in Dutch elderly. Am J Epidemiol. 1990;132:973–82.
5. van Gelder BM, Tijhuis MA, Kalmijn S, Giampaoli S, Kromhout D. Decline in cognitive functioning is associated with a higher mortality risk. Neuroepidemiology. 2007;28:93–100.
6. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimer’s Dement. 2015;11:718–26.
7. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77:461–8.
8. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42–48.
9. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. London: Lancet; 2020.
10. Blair C, Folsom A, Knopman DS, Bray M, Mosley T, Boenwinkle E. APOE genotype and cognitive decline in a middle-aged cohort. Neurology. 2005;64:268–76.
11. Reas ET, Laughlin GA, Bergstrom J, Kritz-Silverstein D, Barrett-Conner E, McEvoy LK. Effects of APOE on cognitive aging in community-dwelling older adults. Neuropsychology. 2019;33:406–16.
12. Acevedo SF, Piper BJ, Craytor MJ, Benice TS, Raber J. Apolipoprotein E4 and sex affect neurobehavioral performance in primary school children. Pediatr Res. 2010;67:293–9.
13. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012;11:1006–12.
14. Davies G, Lam M, Harris SE, Trampush JW, Luciano M, Hill WD, et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat Commun. 2018;9:2098.
15. Davies G, Harris SE, Reynolds CA, Payton A, Knight HM, Liewald DC, et al. A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing. Mol psychiatry. 2014;19:76–87.
16. De Jager PL, Shulman JM, Chibnik LB, Keenan BT, Raj T, Wilson RS, et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging. 2012;33:1017.e1011–1015.

17. Raj T, Chibnik LB, McCabe C, Wong A, Replogsle JM, Yu L, et al. Genetic architecture of age-related cognitive decline in African Americans. Neurol Genet. 2017;3:e125.

18. Picavet HSJ, Blokstra A, Spijkerman AMW, Verschuren WMH. Cohort profile update: the doetinchem cohort study 1987–2017. Lifestyle, health and chronic diseases in a life course and ageing perspective. Int J Epidemiol. 2017;46:1751–1755.

19. Verschuren WM, Blokstra A, Picavet HS, Smit HA. Cohort profile: the Doetinchem Cohort Study. Int J Epidemiol. 2008;37:1236–41.

20. Wareham NJ, Jakes RW, Rennell KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003;6:407–13.

21. Van der Elst W, Van Bostel MP, van Breukelen GJ, Jolles J. The Rey’s verbal learning test: normative data for 1855 healthy participants aged 24–81 years and the influence of age, sex, education, and mode of presentation. Int J Neuropsychological Soc. 2005;11:290–302.

22. Van der Elst W, van Bostel MP, van Breukelen GJ, Jolles J. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24–81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. J Clin Exp Neuropsychol. 2006;28:998–1009.

23. Van der Elst W, Van Bostel MP, Van Breukelen GJ, Jolles J. The Concept Shifting Test: adult normative data. Psychological Assess. 2006;18:424–32.

24. Van der Elst W, Van Bostel MP, Van Breukelen GJ, Jolles J. The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. Assessment. 2006;13:62–79.

25. Nooyens AC, Bueno-de-Mesquita HB, van Bostel MP, van Gelder BM, Verhagen H, Verschuren WM. Fruit and vegetable intake and cognitive decline in middle-aged men and women: the Doetinchem Cohort Study. Br J Nutr. 2011;106:752–61.

26. Illumina. Infinium Global Screening Array-24 Kit. 2017. http://www.illumina.com/assets/2017-infinium-global-screening-array-illumina-data-sheet.pdf.

27. Kassen LC, van Duijn CM, Aulchenko YS. The GenABEL Project for statistical genomics. F1000Res. 2016;5:914.

28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.

29. McCarthy S, Das S, Kretzschmar W, Delanoue O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2014;46:1279–83.

30. Das S, Forer L, Schonner S, Siodre C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48:1284–7.

31. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44:955–9.

32. Trampush JW, Yang ML, Yu J, Knowles E, Davies G, Hagenaes SP, Harris SE, et al. Polygenic predictors of age-related decline in cognitive ability. Mol psychiatry. 2020;25:2584–98.

33. Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71–76.

34. Bennett DA, Wilson R, Schneider J, Evans D, Aggarwal N, Arnold S, et al. Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology. 2003;60:246–52.

35. Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT. APOE ε2 is associated with milder clinical and pathological Azheimer disease. Ann Neurol. 2015;77:917–927.

36. Yu L, Boyle P, Schneider JA, Segawa E, Wilson RS, Leurgans S, et al. APOE ε4, Alzheimer’s disease pathology, cerebrovascular disease, and cognitive change over the years prior to death. Psychol Aging. 2013;28:1015–23.

37. Conejero-Goldberg C, Hyde T, Chen S, Drees-Weringloer U, Hermann M, Kleinman J, et al. Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer’s disease as based on APOE genotype. Mol psychiatry. 2011;16:836–47.

ACKNOWLEDGEMENTS

We thank the participants of the Doetinchem Cohort Study. We would like to thank the field workers of the Municipal Health Services in Doetinchem (C. te Boekhorst, I. Thus, M. Zwijs, and B. Heusinkveld) for their contribution to the data collection of this study. We would also like to thank M. Stynenbosch, H. Hodemaekers-Goossens, E. Zwart and S. Imholz for isolating and measuring the DNA samples for the GWA SNP determinations. We are also grateful to PhD S. Picavet who coordinates the fieldwork since 2007, P. Visrink for logistic management and A. Blokstra for data management (all from the Maastricht Aging Study (MAAS): in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public health Nutr. 2003;6:407–13.

AUTHOR CONTRIBUTIONS

MLR, NCO-M, AMWS, METD, and WMWM designed the study. MLR drafted the manuscript with major contributions from NCO-M, AMWS, METD, and WMWM. DI, KWvD, and JAP performed the quality control and imputation of the GSA-data of the Doetinchem Cohort Study. MLR, ACJN, AMWS, and AW designed the (longitudinal) cognitive psychometric analyses. MLR, NCO-M, LDS, MS, and AW performed/assisted with the data analysis. All authors commented on and approved the manuscript.

FUNDING

This work was supported by the Ministry of Health, Welfare and Sport of the Netherlands, the National Institute for Public Health and the Environment (grant number S132002) and by Biobanking and Biomolecular Resources Research Infrastructure-NL (grant number CP2011-27).

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-02258-5.

Correspondence and requests for materials should be addressed to M. Liset Rietman.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
